Epigenetic Silencing of Interferon-κ in Human Papillomavirus Type 16–Positive Cells
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
We have investigated interferon-κ (IFN-κ) regulation in the context of human papillomavirus (HPV)–induced carcinogenesis using primary human foreskin keratinocytes (HFK), immortalized HFKs encoding individual oncoproteins of HPV16 (E6, E7, and E6/E7), and cervical carcinoma cells. Here, IFN-κ was suppressed in the presence of E6, whereas its expression was not affected in HFKs or E7-immortalized HFKs. Transcription could be reactivated after DNA demethylation but was decreased again upon drug removal. Partial reactivation could also be accomplished when E6 was knocked down, suggesting a contribution of E6 in IFN-κ de novo methylation. We identified a single CpG island near the transcriptional start site as being involved in selective IFN-κ expression. To prove the functional relevance of IFN-κ in building up an antiviral response, IFN-κ was ectopically expressed in cervical carcinoma cells where protection against vesicular stomatitis virus–mediated cytolysis could be achieved. Reconstitution of IFN-κ was accompanied by an increase of p53, MxA, and IFN-regulatory factors, which was reversed by knocking down either IFN-κ or p53 by small interfering RNA. This suggests the existence of a positive feedback loop between IFN-κ, p53, and components of IFN signaling pathway to maintain an antiviral state. Our in vitro findings were further corroborated in biopsy samples of cervical cancer patients, in which IFN-κ was also downregulated when compared with normal donor tissue. This is the first report showing an epigenetic silencing of type I IFN after HPV16 oncogene expression and revealing a novel strategy on how high-risk HPVs can abolish the innate immune response in their genuine host cells. [Cancer Res 2009;69(22):8718–25]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Frommer, M., McDonald, L. E., Millar, D. S., Collis, C. M., Watt, F., Grigg, G. W., Molloy, P. L., & Paul, C. L. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1827 · Cited by 3,238 · cited 1×
“In fact, as revealed by PCR-based “bisulfite sequencing” (42), there is a 148-bp DNA sequence (positions −276 to −128) close to the transcriptional start site that is hypermethylated in E6- and E6/ E7–immortalized HFKs as well as in cervical carcinoma cells but not in E7-expressing cells or primary HFKs (Fig.”
BackgroundPhenotypic plasticity and the epigenetics of human disease
Feinberg, A. P. (2007) · Nature · doi:10.1038/nature05919 · Cited by 1,613 · cited 1×
“The development of cancer can be regarded as an evolutionary process (33), in which genes that are not compatible with cell proliferation are turned off either by irreversible genetic loss or by reversible downregulation through epigenetic means (34).”
BackgroundThe IRF Family Transcription Factors in Immunity and Oncogenesis
Tamura, T., Yanai, H., Savitsky, D., & Taniguchi, T. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090400 · Cited by 1,259
Takaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., et al. (2003) · Nature · doi:10.1038/nature01850 · Cited by 847 · cited 1×
“This supports the previous finding of a functional cross-talk between type I IFN signal transduction and p53 upregulation (49).”
ResultYoneyama, M., Suhara, W., Fukuhara, Y., Fukuda, M., Nishida, E., & Fujita, T. (1998) · The EMBO Journal · doi:10.1093/emboj/17.4.1087 · Cited by 841
The role of type I interferons in TLR responses
Noppert, S. J., Fitzgerald, K. A., & Hertzog, P. J. (2007) · Immunology & Cell Biology · doi:10.1038/sj.icb.7100099 · Cited by 135 · cited 1×
“Although much is known about the function of IFN-α/β in innate and acquired immunity (11, 12), the role of IFN-κ in HPVmediated pathogenesis is still not defined.”
Background
Cited by
Shared and Distinct Functions of Type I and Type III Interferons
Lazear, H. M., Schoggins, J. W., & Diamond, M. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.025 · Cited by 1,138
“HPV epigenetically represses IFN-k expression (Reiser et al., 2011; Rincon-Orozco et al., 2009), suggesting that IFN-k might have a protective role in keratinocytes in the skin and female reproductive tract, although its antiviral properties have not been investigated extensively.”
Graham, S. V. (2017) · Clinical Science · doi:10.1042/cs20160786 · Cited by 456
Persistence of human papillomavirus infection: keys to malignant progression
Bodily, J., & Laimins, L. A. (2011) · Trends in Microbiology · doi:10.1016/j.tim.2010.10.002 · Cited by 339
Yeo-Teh, N. S. L., Ito, Y., & Jha, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061706 · Cited by 273
Host-Directed Antiviral Therapy
Kumar, N., Sharma, S., Kumar, R., Tripathi, B. N., Barua, S., Ly, H., & Rouse, B. T. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00168-19 · Cited by 271
Metadata
- Authors
- Rincon-Orozco, B., Halec, G., Rosenberger, S., Muschik, D., Nindl, I., Bachmann, A., Ritter, T. M., Dondog, B., Ly, R., Bosch, F. X., Zawatzky, R., & Rösl, F.
- Venue
- Cancer Research
- Published
- 2009-11-11
- Volume
- 69
- Issue
- 22
- Pages
- 8718-8725
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2129945630
- Cited by
- 116
- References
- 7
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epigenetic Silencing of Interferon-κ in Human Papillomavirus Type 16–Positive Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-09-0550
- The paper
- Rincon-Orozco, B., Halec, G., Rosenberger, S., Muschik, D., Nindl, I., Bachmann, A., Ritter, T. M., Dondog, B., Ly, R., Bosch, F. X., Zawatzky, R., & Rösl, F. (2009). Epigenetic Silencing of Interferon-κ in Human Papillomavirus Type 16–Positive Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-09-0550
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.